PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Feb 21, 2017
SOUTH PLAINFIELD, N.J., Feb. 21, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 20, 2017 it approved non-statutory stock options to purchase an aggregate of 55,900 shares of its common stock to 14 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ...
Feb 8, 2017
SOUTH PLAINFIELD, N.J., Feb. 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the third annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to patient advocacy organizations to develop unique and collaborative programs ...
Jan 9, 2017
SOUTH PLAINFIELD, N.J., Jan. 9, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it received notification today from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna™ (ataluren). The positive decision is based on the r...
Jan 9, 2017
SOUTH PLAINFIELD, N.J., Jan. 9, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed as part of the company presentation at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 7:30 am PT. Stuart W. Peltz, Ph.D., PTC's Chief Executive Officer, will present th...
Jan 6, 2017
SOUTH PLAINFIELD, N.J., Jan. 6, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RG7916 for the treatment of patients with Spinal Muscular Atrophy (SMA). RG7916 is part of PTC's joint development program in SMA with Roche and the ...
Jan 5, 2017
SOUTH PLAINFIELD, N.J., Jan. 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 3, 2017 it approved non-statutory stock options to purchase 4,000 shares of its common stock to one new employee. The award was made pursuant to the NASDAQ inducement grant exception as a component of our new hire's employment ...
Jan 5, 2017
SOUTH PLAINFIELD, N.J., Jan. 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) initiated a clinical study in infants with Type I SMA. The study, named FIREFISH, will investigate the safety, tolerability and effica...
Jan 3, 2017
SOUTH PLAINFIELD, N.J., Jan. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a corporate update at the upcoming 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 7:30 am PT. The presentation will be webcast live on the Events and Presentations page und...
Dec 16, 2016
SOUTH PLAINFIELD, N.J., Dec. 16, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 14, 2016 it approved non-statutory stock options to purchase an aggregate of 5,600 shares of its common stock to two new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ...
Dec 8, 2016
SOUTH PLAINFIELD, N.J., Dec. 8, 2016 /PRNewswire/-- PTC Therapeutics Inc. (NASDAQ: PTCT), today announced that the company received France's 2016 Prix Galien for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in the Medicines "Rare Disease" category. The award recognizes the scientific innova...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue